Last $10.22 USD
Change Today 0.00 / 0.00%
Volume 1.5M
INO On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Niranjan Y. Sardesai Ph.D.

Chief Operating Officer, Inovio Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 3 different industries.

46$489,444
As of Fiscal Year 2013

Background*

Dr. Niranjan Y. Sardesai, PhD has been the Chief Operating Officer of Inovio Pharmaceuticals Inc since January 2012. Dr. Sardesai served as a Senior Vice President of Research & Development at Inovio Biomedical Corporation. from June 1, 2009 to December 2011. Dr. Sardesai served as Senior Vice President of Research & Development of VGX Pharmaceuticals, LLC from November 2007 to June 1, 2009. Dr. Sardesai served as Vice President of Product Development at VGX Pharmaceuticals, ...

Read Full Background

Corporate Headquarters*

Building 18
Blue Bell, Pennsylvania 19422

United States

Phone: 267-440-4200
Fax: 267-440-4242

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

PhD
California Institute of Technology
MBA
University of Pennsylvania - The Wharton School
MS
IIT Council
BS
Indian Institute of Technology, Bombay

Other Affiliations*

Annual Compensation*

Salary$303,060
Bonus$106,704
Total Annual Compensation$409,764

Stock Options*

All Other Compensation$8,288
Exercisable Options661,860
Unexercisable Options277,500
Total Number of Options939,360

Total Compensation*

Total Annual Cash Compensation$418,052
Total Short Term Compensation$409,764
Other Long Term Compensation$8,288
Total Calculated Compensation$489,444
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $10.22 USD 0.00

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Vijay B. Samant Chief Executive Officer, President, Acting Chief Financial Officer and Director
Vical Incorporated
$557.0K
Steven W. King Chief Executive Officer, President, Director, Chief Executive Officer of Avid Bioservices Inc and President of Avid Bioservices Inc
Peregrine Pharmaceuticals, Inc.
$557.7K
Stanley C. Erck Chief Executive Officer, President, Director and Member of Finance Committee
Novavax, Inc.
$448.3K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$535.6K
Eddie Gray Chief Executive Officer and Director
Dynavax Technologies Corporation
$533.3K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOVIO PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.